Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.

Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.

Rheumatology (Oxford). 2006 Sep;45(9):1121-4. Epub 2006 Mar 1.

PMID:
16510526
2.

[New drugs and treatment strategies for rheumatoid arthritis].

Fantini F.

Recenti Prog Med. 2003 Sep;94(9):361-79. Review. Italian.

PMID:
12942798
3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.

Ariza-Ariza R, Navarro-Sarabia F, Hernández-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J.

Rheumatology (Oxford). 2007 Mar;46(3):529-32. Epub 2006 Sep 29. Review.

PMID:
17012439
5.

Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.

Pharmacotherapy. 2010 Apr;30(4):339-53. doi: 10.1592/phco.30.4.339. Review.

PMID:
20334454
6.

Biologics in rheumatoid arthritis.

Sharma PK, Hota D, Pandhi P.

J Assoc Physicians India. 2004 Mar;52:231-6. Review.

PMID:
15636315
7.

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.

Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL.

Ann Rheum Dis. 2007 Nov;66(11):1473-8. Epub 2007 Apr 10. Review.

9.

Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.

Eng G, Stoltenberg MB, Szkudlarek M, Bouchelouche PN, Christensen R, Bliddal H, Marie Bartels E.

Semin Arthritis Rheum. 2013 Oct;43(2):144-51. doi: 10.1016/j.semarthrit.2013.01.007. Epub 2013 Jul 6. Review.

PMID:
23838092
10.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

11.

Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.

Scrivo R, Conti F, Spinelli FR, Truglia S, Magrini L, Di Franco M, Ceccarelli F, Valesini G.

Reumatismo. 2009 Apr-Jun;61(2):107-17. Review.

12.

[The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication].

Christensen R, Kristensen LE, Geborek P, Danneskiold-Samsøe B, Saxne T, Bliddal H.

Ugeskr Laeger. 2009 Jun 22;171(26):2192-4. Review. Danish.

PMID:
19678436
13.

Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.

Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG.

World J Gastroenterol. 2013 Jul 21;19(27):4344-50. doi: 10.3748/wjg.v19.i27.4344. Review.

14.

[Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].

Pérez Pampín E, Gómez-Reino Carnota JJ.

Med Clin (Barc). 2008 Feb 16;130(5):179-87. Review. Spanish.

PMID:
18341834
15.

Anti-TNF agents for the treatment of psoriasis.

Kircik LH, Del Rosso JQ.

J Drugs Dermatol. 2009 Jun;8(6):546-59. Review.

PMID:
19537380
16.

Patient outcomes after anti TNF-alpha drugs for Crohn's disease.

Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R.

Expert Rev Pharmacoecon Outcomes Res. 2010 Apr;10(2):163-75. doi: 10.1586/erp.10.13. Review.

PMID:
20384563
17.

Anti-TNF-alpha therapy in ankylosing spondylitis.

Wendling D, Toussirot E.

Expert Opin Pharmacother. 2004 Jul;5(7):1497-507. Review.

PMID:
15212600
18.

[Effective combination therapy of TNF antagonists with DMARDs].

Ohtsubo H, Matsuda T.

Nihon Rinsho. 2007 Jul;65(7):1287-91. Review. Japanese.

PMID:
17642245
19.

[Management for TNF failure].

Mukai M.

Nihon Rinsho. 2007 Jul;65(7):1299-307. Review. Japanese.

PMID:
17642247
20.

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents.

Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation.

J Am Acad Dermatol. 2008 Aug;59(2):209-17. doi: 10.1016/j.jaad.2008.03.023. Epub 2008 May 15.

PMID:
18485527

Supplemental Content

Support Center